S Jagannath

Summary

Affiliation: St. Vincent's Comprehensive Cancer Center
Country: USA

Publications

  1. doi Treatment of patients with myeloma with comorbid conditions: considerations for the clinician
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Clin Lymphoma Myeloma 8:S149-56. 2008
  2. doi Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
    Br J Haematol 146:619-26. 2009
  3. doi Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
    Br J Haematol 143:537-40. 2008
  4. ncbi Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, 325 West 15th Street, New York, NY, USA
    Haematologica 91:929-34. 2006
  5. ncbi Pathophysiological underpinnings of multiple myeloma progression
    Sundar Jagannath
    New York Medical College, New York, NY 10011, USA
    J Manag Care Pharm 14:7-11. 2008
  6. doi Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma
    Sundar Jagannath
    St Vincent s Catholic Medical Center, 325 W 15th Street, New York, NY 10011 8202, USA
    Leuk Res 34:1111-8. 2010
  7. ncbi Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology
    Sundar Jagannath
    Department of Medicine, St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Clin Lymphoma Myeloma 7:518-23. 2007
  8. ncbi Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
    S Jagannath
    Department of Medical Oncology, St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Leukemia 21:151-7. 2007
  9. ncbi Current standards for first-line therapy of multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Clin Lymphoma Myeloma 7:S207-14. 2007
  10. ncbi Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Br J Haematol 129:776-83. 2005

Detail Information

Publications56

  1. doi Treatment of patients with myeloma with comorbid conditions: considerations for the clinician
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Clin Lymphoma Myeloma 8:S149-56. 2008
    ..This review will highlight recent trials evaluating novel regimens that promise to improve the standard of care for patients with MM with significant comorbidity...
  2. doi Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
    Br J Haematol 146:619-26. 2009
    ..Bortezomib +/- dexamethasone is an effective and well-tolerated induction regimen for the frontline treatment of MM...
  3. doi Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
    Br J Haematol 143:537-40. 2008
    ..3 mg/m(2) is preferred. If bortezomib dose reduction is required, the 1.0 mg/m(2) dose still offers patients a substantial survival benefit...
  4. ncbi Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, 325 West 15th Street, New York, NY, USA
    Haematologica 91:929-34. 2006
    ..BACKGROUND AND OBJECTIVEs: The efficacy and safety of added dexamethasone were assessed in patients with relapsed and/or refractory multiple myeloma who had a suboptimal response to bortezomib alone...
  5. ncbi Pathophysiological underpinnings of multiple myeloma progression
    Sundar Jagannath
    New York Medical College, New York, NY 10011, USA
    J Manag Care Pharm 14:7-11. 2008
    ....
  6. doi Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma
    Sundar Jagannath
    St Vincent s Catholic Medical Center, 325 W 15th Street, New York, NY 10011 8202, USA
    Leuk Res 34:1111-8. 2010
    ..This review examines the potential of combined proteasome and HDAC inhibition in the treatment of relapsed/refractory MM...
  7. ncbi Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology
    Sundar Jagannath
    Department of Medicine, St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Clin Lymphoma Myeloma 7:518-23. 2007
    ..Clinical applications of these assays will likely increase as their utility is more widely explored...
  8. ncbi Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
    S Jagannath
    Department of Medical Oncology, St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Leukemia 21:151-7. 2007
    ..These matched-pairs analyses suggest that bortezomib may overcome some of the poor impact of del(13) as an independent prognostic factor. However, sample sizes were very small; these findings require confirmation from further studies...
  9. ncbi Current standards for first-line therapy of multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Clin Lymphoma Myeloma 7:S207-14. 2007
    ..The emergence of these new therapeutic options appears likely to significantly alter the first-line treatment paradigm for patients with multiple myeloma...
  10. ncbi Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Br J Haematol 129:776-83. 2005
    ..Bortezomib alone or in combination with dexamethasone is an effective induction therapy with a high CR and nCR rate and manageable toxicities in previously untreated patients with myeloma...
  11. ncbi A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
    S Jagannath
    St Vincent s Catholic Medical Center, New York, NY, USA
    Br J Haematol 127:165-72. 2004
    ..Grade 4 events were observed in 9% (five of 54 patients). Bortezomib alone or in combination with dexamethasone demonstrated therapeutic activity in patients with multiple myeloma who relapsed after frontline therapy...
  12. ncbi The safety and efficacy of bortezomib in relapsed multiple myeloma
    Sundar Jagannath
    Multiple Myeloma Service and Bone Marrow and Blood Stem Cell Transplantation Center, Saint Vincent s Comprehensive Cancer Center, New York City, NY, and New York Medical College, USA
    Clin Adv Hematol Oncol 4:2-3; discussion 8; suppl 13. 2006
  13. ncbi Repeated complete responses with bortezomib in a heavily pretreated primary refractory patient with light chain multiple myeloma
    Meghana Bhandari
    Blood, Stem Cell, and Bone Marrow Transplantation, St Vincent s Comprehensive Cancer Center, New York, NY 10011 8202, USA
    Clin Lymphoma Myeloma 7:373-5. 2007
    ....
  14. ncbi Treatment of myeloma in patients not eligible for transplantation
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, 325 West 15th Street, New York, NY 10011, USA
    Curr Treat Options Oncol 6:241-53. 2005
    ..However, front-line treatment with combinations involving these agents is a promising strategy that may improve the standard of care for patients both eligible and ineligible for stem cell transplantation...
  15. pmc Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications
    Radek Spisek
    Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Blood 109:4839-45. 2007
    ..Specific targeting of bortezomib to tumors may enhance their immunogenicity and the induction of antitumor immunity...
  16. ncbi Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function
    Sundar Jagannath
    Blood Stem Cell and Bone Marrow Transplantation, St Vincent s Comprehensive Cancer Center, New York, New York 10011 8202, USA
    Cancer 103:1195-200. 2005
    ..Bortezomib is a potent, reversible proteasome inhibitor that has been approved for the treatment of recurrent and/or refractory multiple myeloma, but its activity in patients with renal impairment has not been studied to date...
  17. ncbi Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions
    R K Desikan
    Saint Vincent's Comprehensive Cancer Center, 325 W 15th St, New York, NY 10011, USA
    Semin Oncol 28:593-6. 2001
    ..Thalidomide, being a novel drug, presents a number of therapeutic issues that have yet to be resolved...
  18. doi Intracranial multifocal dural involvement in multiple myeloma: case report and review of the literature
    Carlos E Mendez
    Division of Hematology and Oncology, Department of Medicine, St Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
    Clin Lymphoma Myeloma Leuk 10:220-3. 2010
    ..There are no established treatment guidelines for CNS myelomatosis; prognosis and literature on the use of treatment modalities for this complication is reviewed herein...
  19. doi Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice
    Amitabha Mazumder
    St Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
    Clin Lymphoma Myeloma Leuk 10:149-51. 2010
    ..This case series reports our experience of combined vorinostat and bortezomib in 6 patients with relapsed/refractory MM after previous bortezomib...
  20. doi Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma
    Asher A Chanan-Khan
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 50:559-65. 2009
    ..The oblimersen/dexamethasone regimen was generally well tolerated with fatigue, fever and nausea, the most common adverse events reported...
  21. ncbi Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate
    G S Markowitz
    Department of Pathology, Columbia College of Physicians and Surgeons, New York, New York 10032, USA
    J Am Soc Nephrol 12:1164-72. 2001
    ..These data provide the first association of collapsing FSGS with toxicity to a therapeutic agent...
  22. pmc Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy
    Radek Spisek
    Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
    J Exp Med 204:831-40. 2007
    ..Harnessing immunity to antigens expressed by tumor progenitor cells may be critical for prevention and therapy of human cancer...
  23. ncbi Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma
    Raman Desikan
    Myeloma and Transplantation Program, Saint Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
    Br J Haematol 119:496-9. 2002
    ..One other patient continued to show elevated creatinine levels (272.8 micro mol/l). Renal biopsies obtained in two patients revealed focal segmental glomerulosclerosis...
  24. ncbi Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications
    Anjli Kukreja
    Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
    Br J Haematol 136:106-10. 2007
    ..These data suggest that disruption of tumour-DC interactions may contribute to the clinical effects of bortezomib...
  25. ncbi Thalidomide and lenalidomide in multiple myeloma
    Amitabha Mazumder
    New York Medical College, St Vincent s Comprehensive Cancer Center, 325 West 15th Street, New York, NY 10011, USA
    Best Pract Res Clin Haematol 19:769-80. 2006
    ..Thus, both thalidomide and lenalidomide have ushered in a new era of optimism in the management of this incurable cancer...
  26. pmc Enhancement of clonogenicity of human multiple myeloma by dendritic cells
    Anjli Kukreja
    Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
    J Exp Med 203:1859-65. 2006
    ..Together, these data suggest that tumor-DC interactions may directly impact the biology of human tumors, particularly multiple myeloma, and may be a target for therapeutic intervention...
  27. pmc Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
    David H Chang
    Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
    Blood 108:618-21. 2006
    ..Together these data demonstrate that LEN and its analogues enhance CD1d-mediated presentation of glycolipid antigens and support combining these agents with NKT targeted approaches for protection against tumors...
  28. pmc Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma
    Kavita M Dhodapkar
    Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY, USA
    Blood 112:2878-85. 2008
    ..These data demonstrate the capacity of DCs to induce expansion of polyfunctional IL17-producing T cells in humans, and suggest a role for DCs in the enrichment of Th17-1 cells in the tumor bed...
  29. ncbi Novel agents in first-line therapy for myeloma
    Sundar Jagannath
    Multiple Myeloma, Bone Marrow, and Stem Cell Transplantation, St Vincent s Comprehensive Cancer Center, New York, New York, USA
    Oncology (Williston Park) 19:1551-4. 2005
  30. ncbi The current status and future of multiple myeloma in the clinic
    Sundar Jagannath
    New York Medical College, St Vincent s Comprehensive Cancer Center, New York 10011, USA
    Clin Lymphoma Myeloma Leuk 10:E1-16. 2010
    ..This review highlights challenges in the clinic and newer approaches under evaluation for the treatment and/or management of patients with MGUS, SMM, and MM...
  31. ncbi Waldenström's macroglobulinaemia: current therapy and future approaches
    Raman Desikan
    Myeloma and Transplant Service, Saint Vincent s Comprehensive Cancer Center, New York, New York, USA
    BioDrugs 16:201-7. 2002
    ..These agents may also be useful in Waldenström's macroglobulinaemia. Since this is a rare malignancy, all patients should be treated with well-designed clinical protocols to achieve improvement in outcome...
  32. pmc Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer
    David H Chang
    Laboratory of Tumor Immunology and Immunotherapy, Rockefeller University, New York, NY, USA
    Blood 112:1308-16. 2008
    ..These data identify a distinct population of human CD1d-restricted T cells specific for inflammation-associated lysolipids and suggest a novel mechanism for inflammation mediated immune regulation in human cancer...
  33. doi The current status and future of multiple myeloma in the clinic
    Sundar Jagannath
    Multiple Myeloma and Transplant Program, New York Medical College, St Vincent s Comprehensive Cancer Center, New York 10011, USA
    Clin Lymphoma Myeloma Leuk 10:28-43. 2010
    ..This review highlights challenges in the clinic and newer approaches under evaluation for the treatment and/or management of patients with MGUS, SMM, and MM...
  34. pmc Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients
    Nikoletta Lendvai
    New York University Cancer Institute, New York University School of Medicine, New York, NY, USA
    Cancer Immun 10:4. 2010
    ..These data demonstrate that CTAgs, particularly CT7, are immunogenic in MM patients and merit further exploration as targets of immunological therapy in MM...
  35. doi Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma
    Martha Q Lacy
    Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN, USA
    J Clin Oncol 26:3196-203. 2008
    ..A phase I first-in-human study was conducted to characterize the safety, tolerability, pharmacokinetic, and pharmacodynamic properties of the anti-insulinlike growth factor 1 receptor (IGF-IR) monoclonal antibody CP-751,871...
  36. ncbi Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 123:484-9. 2003
    ..In conclusion, a sizeable fraction of myeloma patients relapsing after tandem autotransplants without poor-risk features enjoyed meaningful survival prolongation when appropriately treated...
  37. pmc First thalidomide clinical trial in multiple myeloma: a decade
    Frits van Rhee
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 112:1035-8. 2008
    ..The poor outcome associated with lambda-type myeloma may relate to its overrepresentation in molecularly defined high-risk disease gleaned from studies in newly diagnosed myeloma...
  38. ncbi Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
    Paul G Richardson
    Dana Farber Cancer Institute, Brigham and Women s Hospital, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    J Clin Oncol 24:3113-20. 2006
    ..To determine the frequency, characteristics, and reversibility of peripheral neuropathy from bortezomib treatment of advanced multiple myeloma...
  39. pmc Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
    Sagar Lonial
    Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Blood 106:3777-84. 2005
    ..The exact mechanism underlying bortezomib-induced thrombocytopenia remains unknown but it is unlikely to be related to marrow injury or decreased thrombopoietin production...
  40. ncbi Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
    James R Berenson
    Institute for Myeloma Bone Cancer Research, West Hollywood, California 90069, USA
    Cancer 104:2141-8. 2005
    ..Bortezomib, a first-in-class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma...
  41. ncbi A practical update on the use of bortezomib in the management of multiple myeloma
    Jesus San Miguel
    Hematology Department, Hospital Clinico Universitario de Salamanca, Servicio de Hematologia, Paseo de San Vicente 58, Salamanca E 37007, Spain
    Oncologist 11:51-61. 2006
    ..Information is given on the practical management of the most common adverse events, including peripheral neuropathy and thrombocytopenia, and the use of bortezomib in renal and hepatic impairment...
  42. ncbi Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial
    Paul G Richardson
    Department of Medical Oncology Hematologic Malignancies, Dana Farber Cancer Institute, Brigham and Women s Hospital, 44 Binney Street, Boston, MA 02115, USA
    Cancer 106:1316-9. 2006
    ..Bortezomib, a first-in-class proteasome inhibitor, has shown clinical activity in relapsed, refractory multiple myeloma in a pivotal Phase II trial, SUMMIT...
  43. ncbi Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity
    Paul Richardson
    Division of Hematologic Oncology, Dana Farber Cancer Institute, Boston, Mass 02115, USA
    Mayo Clin Proc 79:875-82. 2004
    ....
  44. ncbi Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma
    Paul Richardson
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Clin Adv Hematol Oncol 4:1; discussion 8; suppl 13. 2006
    ..This review will discuss what is known thus far about the efficacy and safety profile of bortezomib, ways for optimizing treatment with bortezomib, and strategies for managing side effects and enhancing quality of life...
  45. pmc A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 108:3458-64. 2006
    ..Lenalidomide is active and well tolerated in relapsed, refractory myeloma, with the 30-mg once-daily regimen providing the basis for future studies as monotherapy and with dexamethasone...
  46. ncbi The role of thalidomide in multiple myeloma
    Chris Schwab
    CIG Media Group, LP, Dallas, TX 75219, USA
    Clin Lymphoma Myeloma 7:26-9. 2006
    ..This review will focus on recent trials of thalidomide in relapsed/refractory and newly diagnosed multiple myeloma and address some of the common adverse events associated with thalidomide treatment...
  47. ncbi A phase 2 study of bortezomib in relapsed, refractory myeloma
    Paul G Richardson
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 348:2609-17. 2003
    ..Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclinical and phase 1 studies to have antimyeloma activity...
  48. ncbi Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 135:158-64. 2006
    ..038). Ten-year EFS and OS could be accomplished in 15% and 33% of patients, respectively, when all agents available in 1989, especially high-dose melphalan, were applied together upfront for the management of myeloma...
  49. ncbi Bortezomib dosing in relapsed multiple myeloma
    Sundar Jagannath
    Clin Lymphoma Myeloma 7:101-2. 2006
  50. ncbi Plasmacytoma in the breast with axillary lymph node involvement: a case report
    Lesley Taylor
    Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10016, USA
    Clin Breast Cancer 7:81-4. 2006
    ..This could be the first recorded account of plasmacytomas in the breast with axillary lymph node involvement and extracapsular extension of tumor...
  51. ncbi Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
    Paul Gerard Guy Richardson
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    Blood 106:2977-81. 2005
    ..Chromosome 13 deletion and elevated beta2-microglobulin, generally considered poor prognostic factors, were not predictive of poor outcome with bortezomib in this study...
  52. ncbi Infection--an underappreciated cause of bone pain in multiple myeloma
    Raman Desikan
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 120:1047-50. 2003
    ..Previous dexamethasone therapy, together with an episode of bacteraemia, appears to be a predisposing factor for vertebral infection. Magnetic resonance imaging enabled the diagnosis in all three patients...
  53. ncbi American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
    Robert A Kyle
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 25:2464-72. 2007
    ..To update the recommendations for the use of bisphosphonates in the prevention and treatment of bone disease in multiple myeloma. The Update Committee expanded the guideline to include a discussion of osteonecrosis of the jaw (ONJ)...
  54. doi The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement
    M A Hussein
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Leukemia 22:1479-84. 2008
  55. ncbi Engraftment syndrome after hematopoietic stem cell transplantation in multiple myeloma
    Jed Abraham Katzel
    Clin Lymphoma Myeloma 7:151. 2006
  56. ncbi Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression
    John Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 101:3849-56. 2003
    ....